⌕
PTC Therapeutics · PTCT · Nasdaq
Tenet 57 · Mixed
Compare
$63.49+0.21%At closeTenet 57 · Mixed
$63.49+0.13 (+0.21%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

PTC Therapeutics (PTCT) Earnings Forecast

Analysts expect PTC Therapeutics (PTCT) to earn $0.53 a share in FY26, the average of 7 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$0.53
7 analysts
FY27 consensus EPS
$2.73
7 analysts · low $1.49, high $4.47
EPS revisions, 30 days
−57.1%
$1.23 to $0.53
Disagreement, FY26
261.2%
high to low, $−0.39 to $0.99

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect PTC Therapeutics to earn $5.55 a share in FY30, growing about 80% a year; 4 analysts publish an estimate for FY30.

Forward P/E · FY26E
120.7×
$63.49 (as of close, Nov 13, 2026) ÷ $0.53 consensus EPS
Coverage · FY26
7 · 10
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $0.53, down 60.4% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−71.3%−30.2%+10.9%FY27 −1.6%FY26 −60.4%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 6
FY267 analysts▼ −57.1%$1.23 to $0.53▼ −60.4%$1.33 to $0.53▼ −26.9%$0.72 to $0.53
FY277 analysts▲ +10.1%$2.48 to $2.73▼ −1.6%$2.77 to $2.73▲ +9.7%$2.49 to $2.73
Sep '263 analysts▼ −48.6%$0.28 to $0.14▼ −63.6%$0.39 to $0.14▼ −47.8%$0.27 to $0.14
Dec '263 analysts▲ +80.7%$0.19 to $0.35▼ −6.6%$0.37 to $0.35▼ −6.6%$0.37 to $0.35

Contributors at both ends of the window: FY26 5 and 7. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

At 9.8 times earnings, its average over the last five fiscal years, the FY27 consensus of $2.73 works out to $27 a share.

Consensus EPS · FY27
$2.73
7 analysts · low $1.49, high $4.47 · thin coverage
Multiple · five-year average P/E
9.8×
Average of the fiscal-year P/Es, FY25 to FY25.
×
Receipt · PTCT · FY27Nov 13, 2026
Implied, a share
$27

Range on the low and high estimate: $15 to $44.

$15 low$44 high
2.73 × 9.8, to the dollar
Drag the multipleShaded: where PTC Therapeutics' P/E sat at each fiscal year end, FY25 to FY25. Each dot is one year.
5×6×8×10×12×14×15×
5-yr avg 9.8×10-yr median 9.8×$27 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 120.7 times the FY26 consensus for earnings the Street expects to grow about 189% a year to FY28. That rate comes off a base of $0.53 a share, so the multiple is not divided by it here.

How much do analysts disagree?

For FY30, estimates run from $4.82 to $6.35 around an average of $5.55, drawn by 4 analysts.

FY26E7 analysts
$−0.39 to $0.99 · 261.2%
FY27E7 analysts
$1.49 to $4.47 · 109.0%
FY28E11 analysts
$1.48 to $8.88 · 169.1%
FY29E4 analysts
$3.95 to $5.20 · 27.5%
FY30E4 analysts
$4.82 to $6.35 · 27.5%

The dashed line is FY25 filed $7.78, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect PTC Therapeutics to earn $0.35 a share in the December quarter, the average of 3 estimates. We hold no expected date for the next report. Last quarter, which ended in June, PTC Therapeutics earned $0.92 a share. Analysts had expected $0.24, so it came in 289.3% higher.

0
$−1.63
$0.35high $5.20
low $−3.73
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 3 analysts
Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$330.4M
8 analysts, 309.5 to 349.5 in $M · 164.7 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. For the March quarter, analysts expect $0.47 a share.

Does PTC Therapeutics usually beat or miss?

So far we have checked 1 quarter: the one that ended in June 2026, when PTC Therapeutics earned $0.92 a share against the $0.24 analysts expected, 289.3% higher. We add a quarter to this record each time PTC Therapeutics reports.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Sep '23left out
Dec '23left out · basis
Mar '24left out
Jun '24left out · adjusted
Sep '24left out
Dec '24left out
Mar '25left out · basis
Jun '25left out
Sep '25left out
Dec '25left out · basis
Mar '26left out
+289.3%
Jun '26reaction
−9.9%
Dec '26not reported yet
Checked so far
1 quarter
one more every report
Beat expectations
1 of 1
full details on the Earnings tab
Share price reaction
−0.9%
one session, timed to the June 2026 release
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for PTC Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 8.3% in FY27 and EPS 419.0%. Little of it is sales: the net margin moves from 5.3% to 18.5%, and the implied share count from about 133M to 97.1M, so these numbers assume the count keeps falling.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+8.3
Net margin change+271.3
Share count change+139.4
EPS growth+419.0
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
7 analysts publish an EPS estimate for FY26 and 10 publish revenue. Coverage thins with distance: 4 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
107
FY26E
107
FY27E
1211
FY28E
104
FY29E
64
FY30E
The FY26 panel has held 7 analysts every night since our record of it began on Jul 6, 2026.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
0.61.42.2historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 10 revenue estimates for FY26, 6 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−9.410.089.58historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 7 EPS estimates for FY26, 4 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed1.7—7.78————as filedn/m
FY26E1.31.3 to 1.3▼23.7%a0.53−0.39 to 0.99▼93.2%a0.30.10.1310 · 7120.7×
FY27E1.41.3 to 1.6▲8.3%2.731.49 to 4.47▲419.0%0.60.30.1010 · 723.3×
FY28E1.61.3 to 2.1▲14.1%4.381.48 to 8.88n/cb0.70.30.0812 · 1114.5×
FY29E1.81.6 to 2.0▲8.2%4.553.95 to 5.20n/cb0.80.40.0910 · 414.0×
FY30E1.91.7 to 2.1n/cb5.554.82 to 6.35▲22.0%1.00.50.096 · 411.4×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 7 EPS estimates for FY26, 10 for revenue. Not investment advice.

What do analysts expect PTC Therapeutics to earn in FY26?

Analysts expect PTC Therapeutics to earn $0.53 a share in FY26, the average of 7 estimates as of Nov 13, 2026.

What is PTC Therapeutics' earnings forecast for FY27?

The FY27 consensus for PTC Therapeutics is $2.73 a share from 7 analysts, with a low of $1.49 and a high of $4.47, as of Nov 13, 2026.

Have analysts raised PTC Therapeutics' earnings estimates?

PTC Therapeutics' FY26 EPS consensus fell 60.4% in 91 days, from $1.33 to $0.53, as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.